Skip to main content
. 2016 Mar 7;7(16):21713–21727. doi: 10.18632/oncotarget.7964

Figure 6. hBM-MSCs* promote AML chemo-resistance.

Figure 6

A. AML cells were cultured with increasing concentrations of chemotherapeutic agents (Ara-C, Etoposide and Idarubicine). After 48 hours, cell viability was analyzed with MTT assay to identify the EC50. Graphs are representative of 4 independent experiments. B. Cell lines and primary AML cells were treated with Ara-C, Etoposide or Idarubicin in presence or absence of hBM-MSCs*, and then stained with AnnexinV/PI in order to evaluate cell apoptosis. C. Cell lines and primary AML cells were treated with Idarubicin in presence or absence of hBM-MSCs or hBM-MSCs* and then stained with AnnexinV/PI and analysed through flow cytometry. Data are expressed as the mean ± SEM of 5-10 independent experiments involving 10 patients: *p < 0.05, **p < 0.01, **p < 0.001